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      Cyclooxygenase 2 (COX-2) inhibitors and translocator protein 18 kDa (TSPO) drug 
ligands have been shown to have stimulatory effects on steroid production. Given that 
their mechanisms of action differ, we hypothesized that a combination treatment of both 
TSPO drug ligands and COX-2 inhibitors might have additive or synergistic effects on 
steroid production in the Leydig cell.  We tested the effects of each of four COX-2 
inhibitors (Apigenin, DFU, NS398, Indomethacin) and two TSPO drug ligands (Ro5, 
FGIN) on steroid hormone (progesterone) production by MA-10 mouse  Leydig tumor 
cells.  The four COX-2 inhibitors had similar effects across all concentrations when 
inhibitor-treated cells were then incubated with luteinizing hormone (LH).   When cells 
were treated with the COX-2 inhibitor and then incubated with dibutyryl cAMP 
(dbcAMP), dose-response effects were seen.  DFU and Indo were the two COX-2 
inhibitors that had maximal effects on mean progesterone production.  Treatment of cells 
with the TSPO drug ligands, Ro5 and FGIN, also resulted in increased progesterone 
production.  However, we found no additive or synergistic effects of TSPO ligands and 
COX-2 inhibitors when cells were treated in the presence of LH or  dbcAMP.  Thus, 
although the mechanisms by which COX-2 inhibitors and TSPO drug ligands stimulate 
steroid formation differ, treatment of cells by combining the two classes of compounds  
had no greater effect on progesterone production  than either alone.  As yet, however, the 
possibility that these compounds could have additive or synergistic effects has not been 
assessed using primary cells or in vivo. 
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 Steroid hormones play important roles throughout the life course.  Alterations in 
the steroidogenic process can have dramatic effects on the human body regardless of at 
what age alterations occur.  With aging, alterations in steroid production can cause 
problems in mental and physical functioning.  In men, the decline in testosterone 
production that is characteristic of aging can cause symptoms that arguably decrease 
quality of life.  Much work has been done examining how the steroidogenic machinery 
works to produce steroid hormones such as estrogen and testosterone.  By better 
understanding how different cellular components work together to produce hormones, 
there is the potential for novel drug therapies to treat medical conditions arising from 
deficiencies in steroid hormone levels.  One possible way to elevate testosterone in aging 
males is to provide testosterone exogenously.  A more novel approach is to enhance 
testosterone production by the Leydig cells themselves with pharmacological 
intervention.  Two potential classes of chemical compounds, translocator protein 18 kDa 
(TSPO) drug ligands and cyclooxygenase 2 (COX-2) enzyme inhibitors have recently 
been examined for this purpose.  This review will outline the mechanisms behind 
steroidogenesis in the Leydig cells, as well as the therapeutic potential of TSPO drug 
ligands and COX-2 inhibitors. It is possible that when these two pharmacological agents 
are given to Leydig cells as a drug cocktail, they can have an additive or synergistic 
effect on steroidogenesis.  If this is the case, then COX-2 inhibitors and TSPO drug 







In the testis, testosterone is produced by Leydig cells.  In order to study steroid 
production experimentally, the appropriate models must be used.  Various models for 
Leydig cell steroid production exist. Two that have been used extensively are MA-10 
mouse Leydig tumor cells and primary cells, particularly from Brown Norway rats.  Most 
of the experimental data in this thesis was derived using MA-10 Leydig tumor cells, but 
much of the background material that served as the basis for these experimental designs 
also came from rat models.  Leydig cell changes throughout the lifetime have been well 
studied in rats, a common animal model used to study testosterone synthesis.  Brown 
Norway rats in particular are an excellent animal model for the study of steroidogenesis 
due to their similarities in reproductive changes to humans, as well as the absence of 
tumors with aging and overall good general health (Chen et al., 2009).  In rats Leydig 
cells can be classified as fetal Leydig cells that develop in utero, or as adult Leydig cells 
that develop during puberty.  Fetal Leydig cells do not require luteinizing hormone (LH) 
for their development, although they do express the LH receptor and respond to LH 
stimulation.  Adult Leydig cells are responsible for producing the testosterone needed to 
initiate and then maintain spermatogenesis (Chen et al., 2009).  These cells form from a 
distinct four stage model of development: stem Leydig cells, progenitor Leydig cells, 
immature Leydig cells, and adult Leydig cells (Chen et al., 2009).  These four different 
stages have characteristic cellular properties that distinguish them from the others.  For 
example, Leydig cell specific markers such as the LH receptor and 3β-hydroxysteroid 




Leydig cell markers such as the LH receptor and the P450 side-chain cleavage enzyme 
are hallmarks of the transition from stem Leydig cells to progenitor Leydig cells.  The 
progenitor Leydig cells are able to produce steroids, and secrete mostly androsterone 
(Chen et al., 2009).  Advancement to the immature Leydig cell stage is characterized by 
an expansion of the smooth endoplasmic reticulum and increased capacity for 
steroidogenesis. The primary steroid product is 5α-androstane-3α, 17β-diol (ADIOL) 
(Chen et al., 2009).  Adult Leydig cell development is noted when the cells begin to 
produce more testosterone than ADIOL, and these cells do not normally proliferate but 
can regenerate (Chen et al., 2009).   
 The ability of the Leydig cell to react to LH stimulation is a main component of 
the steroidogenic pathway.  However, Leydig cell activity can be influenced by a variety 
of factors; LH signaling is not the only process that can have an effect on steroidogenesis.  
One of these factors is neuropeptide Y.  It was found that injection of neuropeptide Y 
directly into the testes of Sprague-Dawley or Wistar rats blunted the testosterone 
response to human chorionic gonadotropin ( hCG), suggesting that this peptide may act 
independently of LH (Allen et al., 2011). Possible mechanisms suggested for the decrease 
in testosterone include reduced delivery of hCG to Leydig cells or interference with 
testosterone release in the general circulation. The results of this experiment highlight the 
need for further investigation into neuropeptide Y as a potential influence on testicular 
activity through a local site of action (Allen et al., 2011).  So while LH signaling is the 
main focus of the experiments detailed in this thesis, it is noted that various other 





Testosterone Synthesis in the Male Reproductive System 
  Testosterone is produced in the male reproductive system by Leydig cells located 
in the testicular interstitium. As reviewed by Midzak et al. (2009), production of 
testosterone is in response to stimulation by the pituitary gonadotropin luteinizing 
hormone (LH).  In adult Leydig cells, pulsatile secretion of LH by the pituitary gland into 
the peripheral circulation is the driving force behind testosterone production.  Steroid 
synthesis in the Leydig cell is first activated by the binding of LH to the LH receptor on 
the cell membrane, with subsequent initiation of G-protein coupling to the LH receptor, 
activation of adenylate cyclase,  increased intracellular adenosine 3’,5’-cyclic 
monophosphate (cAMP) formation, and phosphorylation processes through protein 
kinase A. A simplified figure of the steroidogenic pathway is presented in Figure 1 
below.    LH action has both short-term and long-term effects, in the latter case 






Figure 1: Diagram depicting the steroidogenic pathway.  Signaling pathways that start the steroidogenic 
process are initiated when the Leydig cell responds to LH.  Taken from Leydig Cell Aging and the Mechanisms 
of Reduced Testosterone Synthesis (Midzak et al., 2009).   
The steroidogenic pathway in the rat has been well studied, with a distinct set of steps 
necessary for the production of testosterone.  This process involves a signaling cascade that 
must be completed stepwise before testosterone can be produced.    All steroid hormones are 
synthesized from cholesterol. The source of this cholesterol is either de novo synthesis from 
acetate in the endoplasmic reticulum, or the import of cholesterol that is bound to circulating 
lipoproteins (Papadopoulos and Miller, 2012).  In humans, cholesterol can come from high 
density lipoproteins, or from low density lipoproteins derived from dietary sources. The latter 
is the main source of steroidogenic cholesterol.  However, rodents differ from humans in that 
high density lipoproteins are the principal source of cholesterol for steroidogenesis 
(Papadopoulos and Miller, 2012).  Low density lipoproteins are stored in droplets as 
cholesteryl esters that can fuse with lysosomes and be degraded to free the cholesteryl esters.  




can then enter the steroidogenic pathway or become re-esterified for storage (Papadopoulos 
and Miller, 2012).       
In order for cholesterol to be converted to another steroid, it must be shuttled to the 
inner mitochondrial membrane where the cholesterol side chain cleavage enzyme 
cytochrome P450 side chain cleavage (P450scc) or cytochrome P450 11A1 ( CYP11A1) is 
located.  It is thought that TSPO is part of a complex of proteins residing in both the inner 
and outer mitochondrial membranes involved in this cholesterol transport (Rupprecht et al., 
2010).  This complex is referred to as the transduceosome, and includes proteins such as 
StAR and the voltage-dependent anion channel (VDAC-1) (Issop et al., 2013).  Other 
components of the transduceosome include TSPO-associated protein 7 (PAP7), ACBD3 
(acyl-CoA-binding-domain 3) and protein kinase A regulatory subunit 1α (PKAR1A) 
(Papadopoulos and Miller, 2012).  Figure 2 shows the various proteins involved in the 







Figure 2:  Various components of the transduceosome involved in steroidogenesis are shown.  The 
transduceosome is named as such because it transduces the cAMP signal at the outer mitochondrial membrane.  
Taken from Organelle Plasticity and Interactions in Cholesterol Transport and Steroid Biosynthesis (Issop et 
al, 2013). 
    Cholesterol does not freely diffuse across the mitochondrial outer membrane through 
intermembrane space to the inner membrane (Midzak et al., 2011).  The conversion of 
cholesterol to pregnenolone on the inner mitochondrial membrane by P450scc/CYP11A1 is 
the primary point of post LH-receptor control during testosterone synthesis due to LH 
stimulation (Midzak et al., 2009).  The transport of cholesterol from cellular stores to the 
inner mitochondrial membrane is cAMP dependent (Midzak et al., 2009).  In response to 




the mitochondria into the inner mitochondrial membrane where the P450 cholesterol side-
chain cleavage enzyme (P450scc/CYP11A1) metabolizes it to pregnenolone (Midzak et al., 
2009).  Conversion of cholesterol to testosterone in the rat Leydig cell involves two principal 
classes of enzymes: the cytochrome P450 proteins (P450scc/CYP11A1 and CYP17) and the 
hydroxysteroid dehydrogenases (3βHSD and 17βHSD).  In a stepwise pattern first 
pregnenolone is synthesized from cholesterol, followed by progesterone, then 17α-
hydroxyprogesterone/androstenedione, followed lastly by testosterone (Midzak et al., 2009).    
Pregnenolone moves out of the mitochondria and to the smooth endoplasmic reticulum where 
it is then metabolized to progesterone by 3β-hydroxysteroid dehydrogenase (3β-HSD).  Then, 
17α-hydroxylase/ C17-20 lyase (CYP17) metabolizes progesterone to androstenedione.  In 
the last step, androstenedione is metabolized to testosterone by type 3 17β-hydroxysteroid 
dehydrogenase (17β-HSD3) (Midzak et al., 2009).    
The LH receptor is a glycoprotein member of the G protein-coupled receptor family 
(Midzak et al., 2009). When LH binds to the LH receptor, stimulatory G proteins (Gs) are 
activated, subsequently relaying a signal to release of GDP by the α subunit of the G protein 
(Midzak et al., 2009).  When the α subunit becomes active (binds GTP), it translocates and 
activates the effector molecule adenylyl cyclase to generate cAMP (Midzak et al., 2009).  
Cholesterol transport across the mitochondrial membrane is dependent on cAMP stimulation 
and involves TSPO and the steroidogenic acute regulatory protein (StAR) (Midzak et al., 
2009).  Cholesterol is transferred to the inner mitochondrial membrane in order to be cleaved 





cAMP and Leydig Cells 
It is known that the amount of cAMP produced in cells due to LH stimulation is 
reduced in aged compared to young cells (Chen et al., 2004).  It is thought that reduced 
cAMP could be a potential player in the demonstrated age related reduction in 
steroidogenesis.  Indeed, it was found that cells from aged rats cultured with dbcAMP were 
able to produce testosterone at levels similar to those seen in young cells, and had increases 
in StAR and P450scc.  Old cells that were treated with dbcAMP for three days produced 
double the amount of testosterone of cells cultured with LH (Chen et al., 2007).   
LH Signaling and Cyclooxygenases 
Prostaglandins play a critical role in a variety of functions throughout the body.    
Prostaglandins are important in the body because of their role in mediating pain and because 
they are implicated in a variety of conditions such as hypertension, cancer, inflammation, and 
normal function of the female reproductive system (Fortier et al., 2008).  Prostaglandins act 
locally in a paracrine or autocrine fashion, and have been found to be produced by all 
nucleated cells of the body (Fortier et al., 2008).  Cyclooxygenases catalyze the conversion 
of arachindonic acid to PGG2 and H2, which is an initial step in prostaglandin biosynthesis 
(Fujimoto et al., 2004).    Two isoforms of cyclooxygenase have been well studied, 
respectively named COX-1 and COX-2.  Whereas COX-1 is a ubiquitous enzyme that 
appears to be involved in a variety of homeostatic functions such as in the kidney, COX-2 is 
thought to be synthesized usually in response to inflammatory stimuli (Fujimoto et al., 2004; 
Seta et al, 2009).  COX-2 is considered the inducible isoform of cyclooxygenase, and is 




1992; Fortier et al., 2008).  While similar, COX-1 and COX-2 also appear to be involved in 
different cellular activities, specifically in relation to the types of prostaglandins they produce 
(Seta et al., 2009).  COX-2 has also been shown to produce prostaglandins from relatively 
low levels of arachindonic acid compared to COX-1 (Parent et al., 2003).  Clinically, 
cyclooxygenases play an important role in pharmacological intervention for a variety of 
diseases.  Nonsteroidal anti-inflammatory drugs (NSAIDs) are known for their anti-
inflammatory, analgesic, and antipyretic properties, which can be attributed to inhibition of 
COX-2 derived prostaglandin production at the site of inflammation (Seta et al., 2009).  
NSAIDs have been used to pharmacologically target prostaglandin production in the body for 
more than a century (Fortier et al., 2008).  It is also known that the production of reactive 
oxygen species and reactive nitrogen species is characteristic of the inflammatory response, 
which can affect cellular function (Fujimoto et al., 2004).  Experiments examining the effects 
of reactive oxygen and nitrogen species on COX-1 and COX-2 activities found that these 
species can have different modulatory effects on these enzymes, with the two isoforms 
showing different sensitivity to the presence of reactive oxygen and nitrogen species.  This is 
important because it is known that a significant amount of reactive oxygen species and 
nitrogen species are formed in inflammatory cells that also contain high amounts of COX-2 
(Fujimoto et al., 2004).  This relationship is significant as COX-2 and its inhibitors have also 
been known to affect steroidogenesis in Leydig cells.   
It is known that LH acts principally through a cAMP dependent pathway to simulate 
cholesterol transport and steroidogenic enzymes (Chen et al., 2007).  In addition to cAMP 
synthesis and signaling, however, LH also induces the release of intracellular arachidonic 




membrane lipids through the action of phospholipase A2 and/or acyl-CoA synthetase (Chen 
et al., 2007).  Arachindonic acid is then metabolized by lipoxygenase, epoxygenase, or 
cyclooxygenase stores in the cell (Midzak et al., 2009).  It is thought that expression of 
cyclooxygenase 2 (COX-2) in the Leydig cells plays a role in the declining levels of 
testosterone production seen in aging Leydig cells (Chen et al., 2007).  COX-2 may in fact 
suppress steroidogenesis since inhibition of COX-2 was shown to increase StAR and 
progesterone production in dbcAMP stimulated MA-10 Leydig tumor cells (Wang et al., 
2003).   
When examining the relationship between COX-2 and LH, it was found that two 
hours of treatment with LH increased COX-2 activity up to 240% of the basal level in 
primary rat Leydig cells.  This effect was also seen when cells were incubated with dbcAMP, 
along with an increase in testosterone production.  When treated with a PKA inhibitor the 
stimulatory effects were inhibited, suggesting that cAMP-PKA signaling plays a role in LH 
stimulation of COX-2 similarly to how it plays a role in testosterone production stimulation.  
In addition, there was a significant increase in COX-2 protein content that was age-dependent 
but also independent of testis weight and testicular germ cell count (Chen et al., 2007).     
Cyclooxygenase-2 Inhibitors 
A variety of COX-2 inhibitors have been used to study how COX-2 activity 
influences steroidogenesis.    One way to do this is to use COX-2 inhibitors to determine how 
COX-2 activity affects LH or cAMP- stimulated steroidogenesis.  When the COX-2 inhibitor 
indomethacin was used to treat MA-10 mouse Leydig cells in conjunction with dbcAMP and 




increase was seen in a concentration- dependent manner.  However, this effect was not seen 
when MA-10 cells were treated with indomethacin alone (Wang et al., 2003).  Using 
indomethacin to inhibit COX activity with dbcAMP also resulted in a significant increase in 
StAR mRNA levels and StAR promoter activity, suggesting that dbcAMP is critical for the 
stimulatory effects of indomethacin.  Similar effects were seen when the COX-2 inhibitor 
NS398 was used.    Within the NS398 treated MA-10 cells, it was found that dbcAMP 
treatment also significantly increased PKA activity and StAR protein expression.  Together, 
the results from this study suggest that COX activity inhibition increases the sensitivity of 
steroidogenesis to cAMP stimulation in MA-10 Leydig cells, and lowers the concentration of 
cAMP necessary for maximal steroid production (Wang et al., 2003).   
Clinically, COX-2 inhibitors have been explored as a therapeutic alternative to 
nonsteroidal anti-inflammatory drugs (NSAIDs).  NSAIDs are associated with major side 
effects on renal function and gastrointestinal events.  NSAIDs are a heterogeneous class of 
drugs with a wide range of selectivity toward COX-1 and COX-2 (Seta et al., 2009).  The 
theory behind COX-2 inhibitor use is that sparing of inhibition of COX-1 activity could 
result in increased safety than when both COX-1 and COX-2 are inhibited (Schnitzer, 2001).  
Selective COX-2 inhibitors were developed on the principle that COX-1 is the constitutively 
expressed isoform of the cyclooxygenase enzyme responsible for housekeeping functions 
such as gastrointestinal cytoprotection, platelet aggregation, parturition, and renal 
homeostasis, whereas COX-2 is expressed only in response to inflammatory and mitogenic 
stimuli (Seta et al., 2009).  Data from clinical trials has shown that COX-2 inhibitor use has 
shown increased gastrointestinal safety, but their use still coincides with some of the same 




COX-2 inhibitors has also been associated with a mild to moderate increase in blood pressure 
as well as papillary necrosis and renal failure (Seta et al., 2009).  COX-2 inhibitors also may 
have a possible association with an increased risk of cardiovascular and cerebrovascular 
disease in clinical trials, which eventually led to their withdrawal from the market 
(Hennekens et al., 2014; Seta et al., 2009).  While COX-2 inhibitor use comes with serious 
side effects, this approach nevertheless remains to be explored further as a potential mediator 
in the steroidogenic response.    
Steroidogenesis in Experimental Models 
When studying steroidogenesis in various models, it should be noted that different 
animal and cell models have characteristics that make one or the other better suited for 
specific studies.  For example, two of the most common models for steroidogenesis, MA-10 
tumor Leydig cells and primary Leydig cells from Brown Norway rats, produce different 
steroids as their final product.  Primary cells produce testosterone, whereas MA-10 cells 
produce progesterone as a result of decreased CYP17 expression.  This makes MA-10 cells 
an inappropriate model for studying the later steps required for testosterone production 
(Midzak et al., 2011).  However, past experiments have shown that mitochondrial ATP 
synthesis is critical for steroidogenesis in both models but the two still have marked 
differences.  For example, glycolysis is a significant source of cellular ATP in MA-10 cells 
while primary cells depend almost completely on mitochondrial respiration for their energy 
sources.  It was also found that ATP levels in MA-10 cells showed greater sensitivity to 
glycolytic inhibition compared to  ATP levels in primary cells.  This same experiment also 
showed that MA-10 cells utilize a greater proportion of glycolytic ATP than primary cells for 




Together these results highlight why data derived from experiments with MA-10 cells cannot 
necessarily be applied to primary cells (Midzak et al., 2011).  This is an important fact to 
remember when translating work done from one model to another.   
MA-10 Cells and Oxidative Stress   
In order to examine the relationship between the redox environment and the 
susceptibility of MA-10 cells to oxidative stress, an altered redox environment was created 
by exposing the cells to buthionine sulfoximine (BSO) or diethyl maleate (DEM) in order to 
decrease glutathione (GSH), after which cells were  exposed to the prooxidant tert-butyl 
hydroperoxide (t-BuOOH) (Chen et al., 2010).  Cells with depleted GSH (an antioxidant 
molecule that plays a role in maintenance of the thiol redox balance in cells) were exposed to 
t-BuOOH. Reactive oxygen species concentration was significantly increased intracellularly, 
and this change also resulted in a significant reduction in progesterone production (Chen et 
al., 2010).  However, inhibition of p38 (a MAPK family member) phosphorylation prevented 
the t-BuOOH driven reduction in progesterone production in GSH depleted cells (Chen et al., 
2010).   This experiment showed that MA-10 cells with a reduced GSH pool were more 
sensitive to acute oxidative stress compared to cells with normal or increased GSH levels, 
and that this susceptibility to oxidative stress is mediated by redox-sensitive MAPK signaling 
pathways.   Because p38 MAPK signaling is an important regulator of COX-2 expression, 
the results of this experiment suggest a potential regulatory network involving oxidative 






Steroidogenesis and Aging 
Testosterone and Aging 
 In humans and in Brown Norway rats,  there are reduced serum testosterone 
concentrations seen with aging (Chen et al., 2009).   Alterations in testosterone production 
are not just due to action in the testes, but can also be attributed to changes in the 
hypothalamic-pituitary axis (Veldhuis et al., 1997; Zirkin and Tenover, 2012).  .  In rats, it 
has been shown that the loss of Leydig cells does not explain age-related reduction in serum 
testosterone levels (Chen at al., 1994).  Rather, there are changes in Leydig cell function, as 
in vitro studies have shown that Leydig cells isolated from aged rat testes produce less 
testosterone than their young counterparts in response to LH (Chen et al., 1994).   
 Declining testosterone production with age could be due to a reduction in 
steroidogenic enzyme activities, the amount of substrate available for steroidogenesis, or a 
combination of these two factors (Culty et al., 2002).  When Leydig cells from young and old 
rats were incubated with human chorionic gonadotropin (hCG), dbcAMP, or 22-
hydroxycholesterol, old cells always produced less testosterone than young cells, but cells 
treated with 22-hydroxycholesterol produced testosterone at a level 5-10 times greater than 
hCG treated cells.  This suggests that the availability of substrate may be a limiting factor in 
steroidogenesis (Culty et al., 2002).  In order to indirectly measure the hormonally induced 
cholesterol pool, young and old Leydig cells were treated with hCG and aminoglutethimide 
(AMG), a P450scc inhibitor, and then mitochondria were isolated in the presence of AMG.  
Upon removal of AMG, the mitochondria of old cells produced only 80% of the steroid of 




cholesterol into the mitochondria than young cells (Culty et al., 2002).  It was also found that 
TSPO mRNA and protein expression were decreased in old cells compared to young ones, 
suggesting that alterations in cholesterol transport may be a critical factor in declining 
testosterone production with age in Brown Norway rat Leydig cells.  Altogether, these results 
suggest that declining cholesterol transport into the mitochondria and changes in TSPO could 
be factors in the declining testosterone production characteristic of aging.   
Experimental evidence has shown that the reduced testosterone levels of aged males 
are not due to reduced LH levels (Zirkin and Tenover, 2012).  This is supported by 
experimental evidence in Brown Norway rats showing that serum LH levels do not 
significantly change with age (Chen et al., 1994).  In fact, the main factor in the decline of 
serum testosterone in aged males is the decreased ability of the testes to synthesize 
testosterone in response to LH (Zirkin and Tenover, 2012).  Specifically, the testes of aged 
Brown Norway rats produced significantly less testosterone compared to the testes of young 
rats when both were perfused in vitro with maximally stimulating LH.  This suggested that 
the  reduced serum testosterone seen in aged rats was due to reduced testosterone production 
by the Leydig cells (Zirkin, et al., 1993).  To test this further, Leydig cells were isolated from 
aged rat testes and were found to produce significantly less testosterone in response to LH 
than cells from young rats (Chen et al., 2009).  Because aged Leydig cells are less responsive 
to LH, this also results in reduced cAMP production in response to LH (Chen et al., 2002).  
This disruption in cAMP signaling is thought to be partially due to decreased LH receptor 
coupling to Gs protein, either through decreased mobility in the plasma membrane due to 
lipid cross-linking (peroxidation model) or through desensitization of the LH receptor due to 




Aged Leydig cells are physiologically different from their younger counterparts.  The 
steroidogenic capacity of Leydig cells is estimated to be reduced by about 50% with aging 
(Zirkin and Tenover, 2012).  However, the reason for this reduction is not due to one single 
factor.  In fact, aged Leydig cells have been shown to have deficiencies in LH receptor 
number  cAMP production, StAR, TSPO, cholesterol transport, and the enzymes required for 
steroidogenesis in the mitochondria and smooth endoplasmic reticulum (Chen et al., 2009).  
Changes in these multiple components of the steroidogenic process have been supported by 
experimental evidence.  In Brown Norway rats, reduction in the ability to produce 
testosterone is partially due to decreased expression of the steroidogenic enzymes (Midzak et 
al., 2009).  In fact, both StAR and TSPO mRNA and protein levels have been shown to be 
diminished with age, as is cholesterol transport into the mitochondria (Culty et al., 2002; 
Midzak et al., 2009).  Aged cells have also been shown to have a decreased response to LH, 
which also contributes to a reduced maximal testosterone synthesis in aged Leydig cells 
(Midzak et al., 2009).  Aged Leydig cells also show increased COX-2 gene expression, 
which is known to inhibit steroidogenesis, possibly due to the increase in arachindonic acid 
metabolism by COX-2 (Chen et al., 2009).   
Redox imbalance and oxidative stress could also play a role in age-related decreases 
in steroidogenesis (Zirkin and Tenover, 2012).  Experimental evidence has shown that certain 
genes responsible for scavenging and/or repairing free radical-induced damage are down-
regulated in aged cells.  Some of these include Cu-Zn superoxide dismutase (SOD1), 
microsomal glutathione S-transferase (MGST1), and glutathione S-transferase (GSTM2) 
(Chen et al., 2009).  Another theory supported by experimental evidence proposes that 




steroidogenesis and/or macrophages could cause damage to cell membrane lipids and 
proteins of the Leydig cell by altering the redox environment that results in reduced LH 
signaling in aged cells (Chen et al., 2009).  Because Leydig cells have an antioxidant network 
devoted to eliminating free radical species, as well as high levels of enzymes able to 
participate in electron transfer, it is thought that this network is vital for protection of cellular 
breakdown due to the presence of oxygen radicals (Midzak et al., 2009).         
In order to elucidate the role of long term LH exposure in Leydig cells, a variety of 
experiments examining the relationship between LH stimulation and ROS formation were 
performed.  Microarray analysis conducted on the Leydig cells of young adult rats stimulated 
by LH showed an up-regulation of genes involved in G protein-coupled receptor activation 
pathways.  Many of these genes were involved in the stress response, including some genes 
known to be protective against cell death.  These results suggested that LH stimulation might 
result in an increase of intracellular oxidative stress, which would subsequently cause cellular 
damage (Beattie et al., 2013).  It was also seen that treatment of both MA-10 Leydig tumor 
cells and young adult rat primary Leydig cells saw an increase in ROS five minutes after 
treatment with LH, but this effect decreased forty-five minutes after stimulation.  This effect 
was also seen in aged Leydig cells, but the time to peak ROS production was longer 
compared to young cells (Beattie et al., 2013).  Incubation of MA-10 cells with LH also 
showed increases in DNA damage, but this damage could be repaired over time or 
suppressed when cells were treated with vitamin E, suggesting that the DNA damage was 
due to ROS generation in the cells.  Together, these results indicate that Leydig cell 
stimulation by LH can induce increased ROS production and DNA damage in young and old 




TSPO and TSPO Drug Ligands 
TSPO, originally named the peripheral benzodiazepine receptor, was discovered due 
to its ability to bind the benzodiazepine diazepam with high affinity (Papadopoulos and 
Miller, 2012).  TSPO can also bind isoquinoline carboxamides (Giatzakis and Papadopoulos, 
2004).  First found in the kidney where radiolabeled benzodiazepine had binding sites, it was 
later confirmed to be present in most tissues of the body (Issop et al., 2013).  Secretory and 
glandular tissues, especially cells that produce steroid hormones, are rich in TSPO whereas 
liver and brain tissue expresses low levels of TSPO (Giatzakis and Papadopoulos, 2004).  
The name TSPO was adopted in 2006 (Rupprecht et al., 2010).   Localized in the outer 
mitochondrial membrane, it is a ubiquitous mitochondrial protein present  in steroidogenic 
tissues including the brain  adrenal glands, and testes (Papadopoulos and Miller, 2012; Issop 
et al., 2013).  There is a high degree of homology between different species in the coding 
region, suggesting that TSPO has been highly conserved throughout evolution (Giatzakis and 
Papadopoulos, 2004).  For example, the promoter for TSPO is highly conserved between the 
mouse and rat genomes, but the promoter is only conserved within the first 150 base pairs 
when comparing mice with humans (Giatzakis and Papadopoulos, 2004).  TSPO is a five 
transmembrane domain protein that is 169 amino acids, and its location in the outer 
mitochondrial membrane suggests it acts as a cholesterol channel to the inner mitochondrial 
membrane (Rupprecht et al., 2010; Papadopoulos and Miller, 2012; Girard et al., 2012).  
Human and rat genes for TSPO have been entirely sequenced, and the gene was found to be 
composed of four exons, of which exon 1 and half of exon 4 are untranslated (Giatzakis and 




amino acid consensus (CRAC) domain where TSPO binds cholesterol (Papadopoulos and 
Miller, 2012; Issop et al., 2013 ).   
 TSPO plays a vital role in the body, a fact supported by the findings that functional 
inactivation of TSPO caused an early embryonic lethal phenotype in mice (Papadopoulos et 
al., 1997; Rupprecht et al., 2010).  Expression of TSPO appears to be regulated by the 
pituitary gland, but may also be affected by IL-1, dopamine, serotonin,  norepinephrine, 
ginkgolide B, TNF-α, and several peroxisome proliferators (Giatzakis and Papadopoulos, 
2004).  Function of TSPO throughout the body may be affected by tissue- and cell-specific 
composition of the mitochondrial membranes (Rupprecht et al., 2010).  TSPO mRNA 
expression profiles found that TSPO mRNA levels are relatively high in the kidney, spleen, 
muscle, lung, adrenal gland, thymus, and stomach in mice.  Intermediate expression levels 
were seen in the pancreas, uterus, prostate, heart, and testis, with low expression levels seen 
in the liver.  Whereas TSPO protein levels seemed to be directly proportional to mRNA 
levels in adrenal glands, the liver, and the brain in this study, they also appeared to be 
inversely proportional in the kidney and testis.  One reason for this could be that TSPO is 
potentially regulated at the transcriptional level in the adrenal glands, liver, and brain but 
postranscriptionally in the kidney and testis (Giatzakis and Papadopoulos, 2004).  A 
comparison of TSPO mRNA and protein levels in Leydig cell MA-10 and adrenal cell Y1 
steroid producing cell lines and non-steroidogenic mouse embryo fibroblasts showed that 
TSPO levels are highest in MA-10 cells, suggesting differential posttranscriptional regulation 
of TSPO (Giatzakis and Papadopoulos, 2004). TSPO has been found to be involved in a 
variety of cellular functions such as oxidative stress, cellular proliferation, programmed cell 




many cellular activities, the focus of this review will be on the role of TSPO in 
steroidogenesis.  
Because the C-terminus of TSPO is exposed to the cytosol, it may play a vital role in 
cholesterol uptake and import into the inner mitochondrial membrane (Rupprecht et al., 
2010).  This ability to bind cholesterol and import it into the mitochondria may also cause 
TSPO to be involved in regulating mitochondrial membrane biogenesis (Rupprect et al., 
2010).  The multifaceted role of TSPO in the body and its importance in steroidogenesis has 
made this protein a fascinating new focus of research on steroidogenic regulation in the body. 
TSPO Ligands  
 Drug ligands of TSPO have been a major point of research into various aspects of 
steroid production throughout the body.  Drug ligands with affinity for TSPO have been 
shown to increase steroid production in the adrenal gland, gonads, and  brain (Papadopoulos 
and Miller, 2012).  They act by stimulating steroidogenic cells to induce the translocation of 
cholesterol from the outer mitochondrial membrane to the inner mitochondrial membrane 
(Papadopoulos and Miller, 2012).   In the testis, TSPO drug ligands have the potential to 
increase endogenous testosterone production in steroid hormone deficient males without 
having to introduce exogenous testosterone to the body.   In the brain, TSPO ligands are 
promising because they can target multiple parts of the neurodegenerative process such as 
neuroinflammation, oxidative stress, mitochondrial dysfunction, and neuronal loss in addition 
to characteristic pathology of these diseases such as β-amyloid protein in Alzheimer’s disease 
(Barron et al., 2013; Rupprecht et al., 2010).   Ligands of TSPO have proved to reduce 




(Rupprecht et al., 2010).  By better understanding how TSPO interacts with cellular 
components of disease, researchers may be able to target aspects of disorders for therapeutic 
applications.   
Cholesterol binds to the cytosolic C-terminus at the conserved CRAC domain of 
TSPO, whereas other TSPO ligands bind to a region in the amino terminus of the protein 
(Rupprecht et al., 2010).    A variety of chemical compounds have been examined as 
potential mediators in the steroidogenic process.  For example, TSPO ligands other than 
cholesterol have been an important target for research into neurodegenerative diseases.  One 
such ligand, Etifoxine, has neuroregenerative effects likely mediated by TSPO and has the 
potential to serve as treatment for peripheral nerve injuries and axonal neuropathies (Girard 
et al., 2011).   
Because many studies showed that TSPO drug ligands could increase steroid 
production in various models of steroidogenic processes, it was proposed that direct 
activation of TSPO through TSPO drug ligands might increase testosterone production in 
Leydig cells (Chung et al., 2013).  To test this hypothesis, the effects of TSPO drug ligands 
Ro5-4864 (a benzodiazepine) and FGIN-1-27 (an indole acetamide) were  examined by 
treating primary cells from young and old Brown Norway rats.  Further, in vivo tests were 
performed in order to see if FGIN-1-27 could increase testosterone production in old animals 
to levels comparable to young rats.  While both young and old primary Leydig cells 
responded to Ro5-498 and FGIN-1-27 with increasing TSPO drug ligand concentration, the 
testosterone production by  aged and young cells to FGIN-1-27 was more dramatic.  Also, 
when Leydig cells were incubated with both FGIN and LH (at a concentration of 0.1 ng/mL), 




with FGIN-1-27 alone.  From these results, it was proposed that Ro5-498 and FGIN-1-27 
stimulated cholesterol transport into the mitochondria through action by TSPO (Chung et al., 
2013).  For in vivo tests, young and aged rats received daily injections of FGIN-1-27 over a 
period of ten days.  After this time frame, testosterone serum levels were measured.  It was 
found that both young and aged rats had higher serum testosterone relative to controls in 
response to FGIN-1-27 treatment.  Data also showed that old rats had serum testosterone 
levels as high as non-stimulated young rats.  These results suggest that TSPO drug ligands 
can bypass cAMP and activate TSPO directly, thereby increasing testosterone formation in 
older cells (Chung et al., 2013).  The therapeutic potential for these results is quite 
significant, as they indicate that activation of TSPO by TSPO ligands could be used for the 
gonadotropin-independent induction of testosterone formation in both primary and secondary 
hypogonadism (Chung et al., 2013).   
Therapeutic Treatments for Reduced Steroid Production 
Before treatment can be offered for reduced testosterone, there must be an agreed 
upon “cutoff” to label a man as testosterone deficient.  This proves problematic as there are 
multiple terminologies used to describe the state of testosterone in the body.  Free 
testosterone and albumin-bound testosterone are what is referred to as bioavailable 
testosterone, but bioavailable levels of testosterone actually decrease to a greater extent than 
total testosterone in the body due to increases in sex hormone-binding globulin levels with 
age (Zirkin and Tenover, 2012).  Regardless, testosterone replacement may offer notable 





Potential Therapeutic Applications for TSPO in Other Systems  
 Much information about the steroidogenic process has been elucidated from studying 
the cellular mechanisms and components involved in this process.  Because TSPO is known 
to play such an important role in the production of testosterone, TSPO drug ligands are 
thought to be potential therapeutic agents that can pharmacologically activate Leydig cells to 
produce testosterone and other steroid hormones as needed.   
Therapeutic Potential for TSPO Outside of the Reproductive System  
While TSPO is found throughout the body, its role in the brain is unique. The 
mechanisms of interaction between the components of steroidogenesis are different in neural 
cells compared to cells in the rest of the body.  For example, the low level of P450scc and its 
mRNA found in the brain and peripheral nervous system suggests regulation of P450scc gene 
expression may be different in the brain compared to other steroidogenic tissues (Zhang et 
al., 1995).  So while the basic biochemical mechanisms underlying steroidogenic action may 
be similar throughout different physiological systems in the body, genetic mechanisms 
controlling how steroidogenic components are expressed and controlled differ.   The 
presence of TSPO in a variety of neurological injuries and disease has been well established. 
TSPO has been found to be a biomarker for inflammation, brain damage including traumatic 
brain injury, and neurodegeneration (Kreisl et al., 2013; Rupprecht et al., 2010).  In many 
parts of the nervous system, changes in how TSPO is expressed are characteristic of disease.   
Expression of TSPO following injury or disease has been seen in both the central and 
peripheral nervous systems at lesion sites. In the peripheral nervous system, TSPO 




can also occur in neurons (Girard et al., 2011).  Upregulation of TSPO in astrocytes and 
microglia due to lesions has a direct association with the degree of damage done to the tissue 
(Rupprecht et al., 2010).  TSPO upregulation has also been implicated as a potential marker 
for degenerative changes in Alzheimer’s disease, frontotemporal dementia, Multiple 
Sclerosis, Huntington’s disease, Amyotrophic Lateral Sclerosis, and Parkinson’s disease 
(Rupprecht et al., 2010).  TSPO expression has also been examined as part of other types of 
brain related disorders.  For example, TSPO was shown to be overexpressed in various 
cancers including brain tumors.  Also, reduced TSPO expression was seen in psychiatric 
disorders such as generalized anxiety disorder, social anxiety disorder, PTSD, and panic 
disorder in the presence of adult separation anxiety disorder (Rupprecht et al., 2010).  In 
addition, TSPO binding may be influenced by drugs given as pharmaceutical treatment for 
neuropsychiatric disorders.  In both animal and cell models, the atypical antipsychotic 
clozapine was found to increase TSPO binding in steroidogenic cells and tissue, suggesting 
that TSPO could play a role in the modulation of steroidogenesis by clozapine (Danovich et 
al.,  2008).   However, animals treated with clozapine in this experiment showed an increase 
in TSPO binding in the hippocampus, hypothalamus, adrenals, and in the testes (Danovich et 
al., 2008).  If TSPO ligands are to be used therapeutically, their effect on multiple systems in 
the body must be considered. While more research is necessary, these results point to the 
importance of TSPO in multiple neurological and neuropsychiatric disorders.  
In the central nervous system, TSPO is expressed primarily in the microglia and 
reactive astrocytes whereas in the peripheral nervous system TSPO is expressed in 
macrophages and/or Schwann cells (Rupprecht et al. 2010).   TSPO is thought to be involved 




this principle that has led to the hypothesis that TSPO ligands can be of therapeutic potential 
similarly to how they may be used in the gonads (Rupprecht et al., 2010).  TSPO ligands 
stimulated steroid hormone production in the testes of both young and old Brown Norway 
rats at equivalent levels, suggesting that these ligands can ameliorate the effects of aging in 
this steroidogenic system (Chung et al., 2013).  If steroid production has been shown to be 
affected by TSPO ligands in the reproductive system, it stands that it may also be a target for 
manipulation in neurosteroid production as well. 
 TSPO has also been implicated in neuronal regenerative processes, and ligands of this 
protein have been investigated as potential therapeutic agents for enhancing neuroprotection, 
increasing axonal regeneration, and influencing inflammation (Rupprecht et al., 2010; Girard 
et al., 2011).  It is thought that TSPO may play a role in the nerve repair process as TSPO 
expression returns to resting levels only when regeneration is completed following peripheral 
nerve injury (Lacor et al., 1999; Rupprecht et al., 2010).   In regards to central nervous 
system diseases, TSPO upregulation and prevalence in a variety of disorders have led 
researchers to hypothesize that targeting TSPO could modify disease progression (Daugherty 
et al., 2013).      
TSPO in Alzheimer’s Disease 
 Alzheimer’s disease (AD) research is another area in which TSPO ligands have been 
examined for their potential therapeutic properties.  3xTgAD mice serve as a rodent model 
for Alzheimer’s disease, and were used in a study to examine if the TSPO ligand Ro5-498 
could serve as a potential therapeutic target for this neurodegenerative disease (Barron et al., 




Rosario et al., 2011; Barron et al., 2013), it was thought that alteration of neurosteroid 
synthesis due to administration of Ro5-498 might have an effect on AD pathology.  Ro5 
treatment was found to attenuate β-amyloid protein accumulation in gonadectomized young-
adult male mice and in aged 3xTgAD mice, decreased gliosis in young-adult gonadectomized 
3xTgAD mice, and increased brain testosterone and progesterone levels in young 
gonadectomized 3xTgAD mice but not aged mice.  There was also morphological evidence 
that Ro5-498 treatment decreased astrocytic and microglial activation in both young and aged 
3xTgAD mice.  Because anxiety may be an early indicator of AD in people with mild 
cognitive impairment, TSPO ligand affect on anxiety-related behavior was measured in 
3xTgAD mice.  Mice treated with Ro5-498 exhibited a trend toward decreased anxiety-
related behavior (Barron et al., 2013).  These findings suggest that TSPO ligands can have a 
versatile role in AD research, representing a marker for neuroinflammation, acting as a 
possible anti-inflammatory treatment, and  having a therapeutic effect on clinical features of 
AD such as anxiety (Barron et al., 2013).   
 TSPO ligands have therapeutic potential because of their ability to   influence 
neurosteroid production at the point of cholesterol uptake (Irwin and Brinton, 2014).  This is 
important because neurosteroids have been shown to affect and sometimes reverse 
Alzheimer’s disease pathology.  Allopregnanolone is an endogenous neurosteroid that 
declines with age and also during the course of neurodegenerative disease.  This neurosteroid 
has also been shown to promote neurogenesis, improve cognitive capabilities, and reduce AD 
pathology in mice (Irwin and Brinton, 2014).  However, therapeutic treatment with 
neurosteroids poses some problems.  Questions of the optimal treatment paradigm arise in 




neurogenic changes, especially since high doses of allopregnanolone and chronic treatment 
have been shown to impair learning and memory capabilities (Irwin and Brinton, 2014).  
Also, the majority of neurosteroids are not well suited for oral delivery due to poor solubility 
properties and poor bioavailability caused by the fact that neurosteroids precipitate readily 
from aqueous environments.  These non-optimal chemical properties have led researchers to 
investigate other means to administer allopregnanolone besides oral dosage (Irwin and 
Brinton, 2014).  TSPO ligands may offer hope as a novel method to induce endogenous 
hormone synthesis of neurosteroids, and thus bypass the problems mentioned above while 
still reaping the benefits of increased steroid levels.   By targeting the brain’s regenerative 
system and intervening with AD progression early on through new pharmacological 
treatments, headway may be made in addressing the millions of people affected by this 
disease (Irwin and Brinton, 2014).   
TSPO in Multiple Sclerosis 
 Various TSPO ligands have shown promise in the treatment of Multiple Sclerosis 
(MS).  One such ligand, etifoxine, was originally designed to be an anxiolytic agent but was 
later determined to have a strong affinity for TSPO (Daugherty et al., 2013).  Because MS 
patients show a drop in neurosteroid levels and treatment with neurosteroids has been shown 
to lead to a partial rescue in a mouse model of MS, etifoxine was studied in order to 
determine if it had protective and regenerative effects on inflammatory demyelination in a 
mouse model of MS.  Etifoxine treatment was shown to promote steroidogenesis and 
possibly inhibit peripheral immune cells in this model.  Etifoxine-treated mice also showed a 
delay in onset of the first signs of clinical symptoms and a decrease in the peak of clinical 




peripheral immune cell infiltration of the spinal cord was observed, as well as increased 
oligodendroglial regeneration after inflammatory demyelination in the mouse model of MS.  
Together, these results suggest that etifoxine is both protective and promotes recovery in a 
mouse model of MS (Daugherty et al., 2013).   
 Another study conducted by Harberts et al. (2013) examined the use of a newly 
synthesized TSPO ligand, PBR28, in an in vitro radioligand binding assay to quantify 
peripheral TSPO in peripheral blood mononuclear cells from MS patients and healthy 
controls.  PBR28 had already been shown to correlate with active demylinating lesions found 
during MRI in MS patients.  Patients with MS were found to have a significantly lower 
amount of peripheral TSPO compared to the healthy control group.  This finding in the PNS 
is in contrast to damage in the CNS in which TSPO is upregulated in response to disease 
state.  This reduction in peripheral TSPO expression may be due to sequestration of  
macrophages expressing high levels of TSPO in the tissue, and can thus be explored as a 
potential peripheral biomarker of MS (Harberts et al., 2013).   
TSPO in Neuroimaging 
 There has been an increased interest in the use of TSPO ligands as neuroimaging 
agents in recent literature.  Radiolabeled ligands have been investigated as diagnostic tools 
and markers for the state and progression of neuronal injury and neurodegenerative disease 
(Rupprecht et al., 2010).  Because TSPO upregulation in neuronal cells is associated with the 
degree of damage in those cells, TSPO imaging can be useful when assessing brain lesions 
with pathogenic heterogeneity such as following strokes (Rupprecht et al., 2010).   TSPO 




in recent studies.  One study by Kreisl et al. (2013) used the radioligand 11 C-PBR28 in an 
attempt to determine if TSPO binding was different between groups of patients with 
Alzheimer’s disease, mild cognitive impairment, and healthy older controls.  Then, TSPO 
binding was analyzed to see if it corresponded with neuropsychological measures, grey 
matter volume, 11 C-Pittsburg Compound B binding (PIB), or in age of onset.   Differences in 
binding was demonstrated through the different experimental groups, with AD patients 
showing greater 11 C-PBR28 binding in cortical brain regions known to be affected by AD 
pathology than controls, but this effect was not seen in patients with mild cognitive 
impairment (MCI).   11 C-PBR28 binding was also found to be inversely correlated with 
performance on the neuropsychological battery of tests as well as with grey matter volume.  
Interestingly, 11 C-PBR28 binding (particularly in the parietal cortex) was associated with 
earlier age of onset.  11 C-PBR28 binding indicated the presence of neuroinflammation, and 
so increased 11 C-PBR28 binding to TSPO after conversion of MCI to AD correlated with 
greater neuroinflammation and worsened disease progression.    This suggests that 11 C-
PBR28 can be used to measure increased TSPO expression by activated microglia, which 
occurs after the conversation between disease states.    The differences in 11 C-PBR28 
binding in early onset compared to late onset AD patients led to the hypothesis by the authors 
that microglial activation may be the driving pathogenic factor in early onset AD as opposed 
to amyloid burden, and might offer an explanation as to why early onset patients display 
more severe executive and visuospatial deficits compared to older onset individuals.  These 
results also show that the radioligand 11 C-PBR28 may be utilized in longitudinal studies to 
mark the conversion from MCI to AD, or could be used to assess the response to 




activation in subjects with MCI, this could just be due to the fact that 11 C-PBR28 is not 
sensitive enough to detect TSPO density in these patients.  (Kreisl et al., 2013). 
Another study by Yasuno et al. (2012), suggests the potential for TSPO binding 
measured by PET imaging as a way to monitor neurodegenerative disease progression.  
TSPO binding has been shown to reflect activated microglia, which also serves as a 
predictive biomarker of conversion from mild cognitive impairment to dementia (Yasuno et 
al., 2012).  This study used the TSPO ligand [11C]Daa1106 to measure TSPO binding in mild 
cognitive impairment, Alzheimer’s disease, and age-matched control groups.  TSPO was 
quantified by binding potential, and a portion of the MCI group was followed for five years 
after the initial PET scan to monitor disease progression.  Strikingly, [11C]Daa1106 binding 
to TSPO was increased significantly in widespread areas in the MCI groups compared to 
controls, although there was no significant difference  between MCI and AD patients in all 
measured regions.  However, the widespread binding of [11C]Daa1106 in MCI and AD 
patients due to reactive microglia and astrocytes was not linked spatially to β-amyloid and 
tau pathology.  In addition, MCI patients with [11C]Daa1106 binding values higher than the 
control mean by +0.5 standard deviations developed dementia within five years of the 
original imaging studies.  These results suggest that microglial activation as indicated by 
higher [11C]Daa1106 binding can occur before the clinical onset of symptoms of dementia, 
and could be a predictive biomarker of early stage disease.   This offers promise in being able 
to recognize MCI patients at a higher risk of conversion to dementia by TSPO imaging 






 While much is known about the steroidogenic process in the body, there is still much 
to be learned.  Steroid production is a finely tuned process that proceeds in a stepwise 
manner involving many different cellular components.  Because there are so many steps 
involved, there are also many ways in which those cellular components can cause problems.  
Alternatively, there are also many ways in which those same cellular components can be 
manipulated in order to ameliorate deleterious effects.  Many of these have been outlined in 
the above review.   COX-2 inhibitors and TSPO drug ligands are of particular interest 
regarding their role in testosterone production in the aging Leydig cell.  There is much 
therapeutic potential for these two pharmacological treatments in the steroidogenic process.  
Particularly in the male reproductive system, COX-2 inhibitors and TSPO drug ligands have 
the potential to offer an alternative pharmacological treatment for increasing testosterone 
synthesis in aging males.  As can be seen through the extensive data on the potential use of 
TSPO drug ligands in the neurological system, the therapeutic applications of these drugs 
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Reduced serum testosterone (T), or hypogonadism, is common in aging men.  
Approximately 20-50% of men over age 60 are reported to have serum T levels significantly 
below those of young men (age 20-30 years) (Harman et al., 2001; Surampudi et al, 2012). 
Adult Leydig cells synthesize T under the control of luteinizing hormone (LH) from the 
pituitary gland. Age-related decline in serum T levels in many hypogonadal men, however,  
is not in response to reduced LH from the pituitary gland (secondary hypogonadism), but 
rather a consequence of Leydig cells becoming less responsive to LH (Surampudi et al., 
2012; Zirkin and Tenover 2012). This is referred to as primary hypogonadism.  Whether in 
aging or young men, reduced serum T has been linked to a number of metabolic and quality-
of-life changes, including decreased lean body mass and bone mineral density, decreased 
muscle mass and strength, adiposity, cardiovascular disorders, decreased libido and sexual 
function, as well as altered mood and fatigue (Surampudi et al., 2012).   
One way to treat the symptoms of low T is through exogenous T replacement.  
Exogenous T preparations can be used to raise serum T levels and treat the symptoms of low 
T. The T preparations in use to achieve this are injections, scrotal and nonscrotal transdermal 
patches, and oral, buccal and gel preparations.  Testosterone injections and testosterone gel 
preparations are two of the most commonly used replacement methods in the United States 
(Surampudi et al., 2012). With injections, serum T levels can vary, which requires T levels to 
be measured and sometimes adjusted between injections. T administered by gels and other 
transdermal methods produce more constant T concentrations, but these methods have the 
potential for unwanted T transfer via skin contact (Surampudi et al., 2012). Testosterone 




cardiovascular complications, sleep apnea, polycythemia and prostatic disease (Surampudi et 
al., 2012). Moreover, the administration of exogenous T by any means can suppress 
gonadotropin release from the pituitary, leading to reduced intratesticular testosterone and 
consequently reduced sperm production. Thus, the exogenous administration of T to 
ameliorate hypogonadism could affect fertility (Surampudi et al., 2012).  
Increasing serum (and intratesticular) T by stimulating the Leydig cells themselves 
rather than administering exogenous T could have great advantages. Increasing Leydig cell T 
production should result in the physiological regulation of T by its negative feedback on LH. 
This is in contrast to essentially flooding the system with T, as with exogenous T 
administration. This method is advantageous because it does not pose the risk of some side 
effects seen with exogenous T administration.  This approach should elicit fluctuations in T 
levels in response to negative feedback of T on LH, as occurs normally.  There would not be 
the potential for T transfer to others via contact. Fertility should be preserved, not 
suppressed, because the hypothalamic-pituitary axis should not be shut down as with 
exogenous T. Indeed, the local stimulation of Leydig cell T production might actually 
enhance spermatogenesis because intratesticular T levels should increase, not decrease, and 
because the Leydig cells produce more than just testosterone.  
How might the Leydig cells in individuals with primary hypogonadism be stimulated 
to produce T?  In Leydig cells, LH binds to and activates G protein-coupled receptors, 
resulting in the activation of adenylyl cyclase and thus in increased cAMP formation. The 
acute stimulation of Leydig cells by LH results in cholesterol transfer from intracellular 
stores into the mitochondria, which is the rate-limiting step in steroid biosynthesis.  This is 




cleavage cytochrome P450 enzyme (CYP11A1), located on the matrix side of the inner 
mitochondrial membrane. Pregnenolone is then converted to testosterone in the smooth 
endoplasmic reticulum (Midzak et al., 2009). Translocator protein (TSPO) is part of a 
complex of proteins residing in both the inner and outer mitochondrial membranes involved 
in this cholesterol transport (Rupprecht et al., 2010).  The C-terminus of this protein contains 
a cholesterol-recognition amino acid consensus (CRAC) domain where TSPO binds 
cholesterol (Papadopoulos and Miller, 2012; Issop et al., 2013).  Numerous previous studies 
have shown that TSPO drug ligands are able to stimulate steroid formation in steroidogenic 
cells (Chung et al., 2013; Papadolpoulos and Miller, 2012).   
Previous studies demonstrated that the direct, pharmacological activation of TSPO 
with the TSPO drug ligand FGIN-1-27 (N,N-dihexyl-2-(4-fluorophenyl)indole-3-acetamide) 
increased T production by young and aged Leydig cells (Chung et al., 2013). The stimulatory 
effect of FGIN-1-27 was abolished by the TSPO cholesterol recognition/interaction amino 
acid consensus (CRAC) domain inhibitor 3,17,19-androsten-5-triol (19-Atriol). FGIN-1-27 
also had effects when administered in vivo. Thus, administering FGIN-1-27 to aged rats 
elevated serum T to the level of young rats. These studies showed that the pharmacologic 
activation of TSPO could increase T production and led to our decision to evaluate the 
potential use of TSPO drug ligands as one means to induce T formation by steroid-forming 
cells.  
Another class of chemical compound, COX-2 inhibitors, also has been examined as a 
means by which to increase T production by Leydig cells. LH acts principally through a 
cAMP dependent pathway to simulate cholesterol transport and steroidogenic enzymes (Chen 




release of intracellular arachindonic acid, which is metabolized by lipoxygenase, 
epoxygenase, or cyclooxygenase stores in the cell (Midzak et al., 2009).  It is thought that 
expression of cyclooxygenase 2 (COX-2) in the Leydig cells plays a role in the declining 
levels of testosterone seen in aging Leydig cells (Chen et al., 2007).  COX-2 may in fact 
suppress steroidogenesis since inhibition of COX-2 was shown to increase StAR and 
progesterone production in MA-10 Leydig cells stimulated with dbcAMP (Wang et al., 
2003).  The observation that inhibition of COX-2 activity increases the sensitivity of 
steroidogenesis to cAMP stimulation in MA-10 Leydig cells, and lowers the concentration of 
cAMP necessary for maximal steroid production (Wang et al., 2003), resulted in our decision 
to evaluate the potential use of COX-2 inhibitors and TSPO ligand combinations on steroid 
formation.   
In sum, two cellular components, COX-2 inhibitors and TSPO drug ligands, are of 
particular interest regarding their role in steroid formation. The rationale for conducting 
studies of combinations of the two is that separately or together, COX-2 inhibitors and TSPO 
drug ligands have the potential to offer an alternative pharmacological treatment to combat 









MATERIALS AND METHODS 
Reagents 
     Apigenin, indomethacin (indo), dbcAMP, Ro5-4864, FGIN-1-27, Waymouth MB752/1 
medium, horse serum, and Hanks’ Balanced Salt Solution were obtained from Sigma-Aldrich 
(St. Louis, Missouri).  M-199 was from Gibco BRL (Grand Island, New York).  Progesterone 
antibodies were obtained from MP Biomedical (Solon, Ohio).  Bovine LH (USDA-bLH-B6) 
was provided by the US Department of Agriculture Animal Hormone Program (Beltsville, 
Maryland). NS398 was from Cayman Chemical (Ann Arbor, MI). 5,5-Dimethyl-3-(3-
fluorophenyl)-4-(4-methylsulfonyl) phenyl-2((5)H)-furanone (DFU) was kindly provided by 
Dr. Denis Riendeau from Merck Frosst Canada Ltd. (Kirkland, Quebec, Canada). 
MA-10 Cell Culture 
     MA-10 mouse Leydig tumor cells were a gift from Dr. Mario Ascoli (University of Iowa, 
Iowa City, IA).  The cells were grown in Waymouth’s MB752/1 medium containing 15% 
horse serum and 5% CO2 at 34º (Chen et al., 2010).  Cells were grown in 24 well plates, and 
treated when they reached 70-80% confluence.  When cells were undergoing treatment with 
LH, dbcAMP, COX-2 inhibitors, or TSPO drug ligands, serum-free M199 medium was used.  
The medium was frozen for progesterone assay and the cell plate was frozen for future 
protein assays.   
MA-10 Cell Treatment with LH, dbcAMP, and COX-2 Inhibitors 
     MA-10 cells were grown on a 24 well plate in Waymouth MB752/1 medium with 15% 




treated with one of four different COX-2 inhibitors (Apigenin, DFU, NS398, or Indo).  
Serum-free M-199 medium containing 0.1% BSA was used during treatment.  The different 
COX-2 inhibitors were dissolved in DMSO and then diluted in the culture medium with the 
final concentration of DMSO in the medium always being less than 0.2%.  Cells were treated 
with five different concentrations of COX-2 inhibitors:  0.1 µM, 0.33 µM, 1.0 µM, 3.3 µM, 
or 10 µM.  Cells were incubated for 30 min at 34º C with the COX-2 inhibitors.  After this 
period, cells were treated with either culture medium alone (control), LH or dbcAMP, and 
incubated for 2 hr at 34º C with the continued presence of the inhibitors.  After this 
incubation, medium was collected from each well and immediately frozen at -20ºC for 
progesterone assay.  Progesterone levels were assayed by radioimmunoassay (RIA).   
MA-10 Cell Combination Treatment with COX-2 Inhibitors and TSPO Drug Ligands  
     For the combination treatment, MA-10 cells were treated with one of two different COX-
2 inhibitors, DFU or Indo. Cells were also treated with one of two different TSPO drug 
ligands, Ro5-4864 or FGIN-1-27.  The procedure was the same as described above, with the 
cells incubated with the COX-2 inhibitor and TSPO drug ligand combination for 30 min 
before the addition of LH or dbcAMP.  Cells were treated with COX-2 inhibitors alone, 
TSPO drug ligands alone, or in combination.  Cells that only received either a COX-2 
inhibitor or TSPO drug ligand were given an additional amount of DMSO in order to balance 
out well volumes. Cells were then incubated for 30 min at 34º C.  After this 30 min 
incubation, cells were treated with either culture medium, LH, or dbcAMP and incubated for 
2 hr at 34º C with the continued presence of the inhibitors.  After this incubation, medium 
was collected from each well and immediately frozen for later progesterone assay by RIA. 





     The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay was used 
to assess cell viability (Mossman, 1983; Chen et al., 2010). After treatment with COX-2 
inhibitors and TSPO drug ligands for two hours, cells were incubated with M199 medium 
containing MTT (0.5mg/ml) for one hour.  In the viable cells, the MTT can be converted into 
blue formazan. The medium was then removed and the plate was frozen at -80ºC to be tested 
at a later date.  When the assay was to be performed, the reduced formazan in each well 
was dissolved with 200 µL acidified (0.04 N HCl) isopropanol at room temperature for 30 
minutes.  The solution from each well was then transferred to a new 96-well plate and 
read by a DTX800 Multimode Detector (Beckman, Coulter, Inc., Fullerton, CA) at 562 nm 
wavelength. Cells from three different experiments were analyzed for each treatment with 
COX-2 inhibitors, TSPO drug ligands, and 0.5 ng/mL LH stimulation. 
Statistical Analysis 
Data are expressed as Mean +/- standard error of the mean (SEM).  One-way 
ANOVA was used to evaluate group means.  If differences between groups were detected by 
ANOVA (p< 0.05), then differences between individual groups were determined by the 










    COX-2 inhibitors and TSPO drug ligands have been shown to have stimulatory effects on 
steroid production (Chung et al., 2013; Wang et al., 2003).  The primary objective of this 
Master of Science research was to determine whether a combination treatment of COX-2 
inhibitors and TSPO drug ligands would have effects that differ from their individual effects 
on steroid production by MA-10 Leydig cells.  To this end, MA-10 cells were cultured with 
inhibitor and/or ligand in the presence of LH or dbcAMP, and their separate and combined 
effects on the production of progesterone were measured.    
     We first determined the effect of increasing concentrations of LH alone on progesterone 
production by MA-10 Leydig cells. For this study, cells were cultured for 2 hours with 
increasing concentrations of LH (0-100 ng/ml), and progesterone concentration in the media 
was measured by RIA.  As seen in Figure 1, LH at 0.01 ng/ml had little effect. A significant 
increase in progesterone production was seen in response to 0.1 ng/ml. At concentrations 
between 1 and 100 ng/ml, progesterone was maximally stimulated.  
     We next assessed the effect of increasing concentrations of COX-2 inhibitors on 
progesterone production.  The objective was to determine at least preliminarily the relative 
effects of the inhibitors on progesterone formation.  MA-10 cells were incubated for 30 
minutes with apigenin, DFU, NS398, or indomethacin (Indo), at concentrations from 0.1 uM 
to 10 uM. Then, LH at a concentration of 0.1 ng/ml (Fig. 2A) or  1.0 ng/ml (Fig. 2B) was 
added, and the cells were incubated for an additional two hours. After treatment, media 
samples were collected and progesterone levels were measured. The studies were repeated 




dramatically different effects from each other on progesterone production in response to 0.1 
ng/ml LH, regardless of dose. Rather, progesterone levels were relatively low across all 
concentrations of COX-2 inhibitors tested.  When tested at an LH concentration of 1.0 
ng/mL, a concentration at which progesterone levels were considerably higher, the four 
COX-2 inhibitors again produced similar effects across all five concentrations tested.  We 
noted that the highest progesterone production was seen when DFU was used at a 
concentration of 10 µM (Fig. 2B).  
      Figures 3A-D compare the  dose-dependent effects on progesterone production in 
response to each of the four COX-2 inhibitors (apigenin, Fig. 3A; DFU, Fig. 3B; NS398, Fig. 
3C; and Indo, Fig. 3D). As above, the cells were treated with COX-2 inhibitor, and then LH 
was added at 0.1 or 1 ng/ml.  In each case, progesterone levels were significantly greater 
when LH was at a concentration of 1.0 ng/mL.  However, it is apparent there was little 
difference among the five different doses of COX-2 inhibitors whether LH was either 0.1 or 
1 ng/ml.   This confirmed that the COX-2 inhibitors elicited similar effects to one another. 
     Cyclic AMP is produced in response to LH/receptor binding and is integrally involved in 
cholesterol translocation from the cytosol to the inner mitochondrial membrane, the rate-
determining step of steroid formation (Midzak et al., 2009).  Previous experiments have 
shown that dbcAMP stimulation can increase steroidogenesis (Chen et al., 2007). We 
conducted a series of studies in which MA-10 cells were incubated with increasing 
concentrations of each of the four COX-2 inhibitors, but with stimulation by dbcAMP rather 
than with LH.  As with the LH regimen, cells were incubated with a COX-2 inhibitor for 30 
minutes, and then dbcAMP was added at a concentration of 0.1 mM (Fig. 4A) or 0.05 mM 




apigenin or DFU along with 0.1 mM dbcAMP, there were significant, 4-5-fold increases in 
progesterone production in comparison to stimulation with NS398 or Indo at that same 
concentration.  At lower concentrations (0.1 – 3.3 uM), there was little difference in the 
stimulation of progesterone production by the four COX-2 inhibitors.  With 0.05 mM 
dbcAMP (Fig. 4b), progesterone production was again very high with DFU at 10 uM, though 
not with apigenin.  At lower concentrations (0.1 um, 0.33 uM and 1 uM), Indo stimulation 
also resulted in relatively high progesterone production. 
     From these results, which differed somewhat from those obtained with LH, we proceeded 
to examine the effects of TSPO drug ligands with DFU or Indo co-stimulation.  Our objective 
was to determine whether using COX-2 inhibitors and TSPO drug ligands in combination 
had a different outcome than using the inhibitors and ligands separately.   . The TSPO drug 
ligands used were Ro5-4864 (Ro5) and FGIN-1-27 (FGIN).  The treatments that were used 
are shown in Figure 5. For these studies, cells were incubated with COX-2 inhibitor, TSPO 
drug ligand, or a combination of the two for 30 min. Then LH or dbcAMP was added, the 
cells were incubated for an additional 2 hours, and progesterone in the media was measured.  
     Mean progesterone levels for each treatment stimulated with LH can be seen in Figures 
6A-6D.    With 0.1 ng/ml LH (Fig. 6A), progesterone production was comparable by cells 
treated with the COX-2 inhibitors DFU and Indo. Stimulation by the TSPO drug ligand Ro5 
resulted in progesterone production at levels that were comparable to those with DFU or 
Indo.  Progesterone levels in response to the two TSPO drug ligands differed; stimulation 
with FGIN resulted in progesterone production that was about half that of Ro5. Progesterone 
production by combinations of Ro5+DFU and Ro5+Indo were not different from production 




production that was lower than, though not significantly different from, FGIN alone.  But 
FGIN + Indo resulted in progesterone levels that were lower than Indo alone.  There was no 
statistically significant difference between the different treatment regimens (P>0.05).  
However, standard error bars were not expressed for FGIN + DFU treatment (n=2), so 
statistical analysis does not include this treatment.  As seen in Figures 6B and 6C, 
comparable results were seen when LH stimulation was at 0.2 ng/ml and 0.5 ng/ml , 
respectively.  There was no statistically significant difference between treatment regimens 
when 0.2 ng/mL LH stimulation was used (P>0.05).  However, there were statistically 
significant differences observed when 0.5 ng/mL LH stimulation was used (P<0.05).  In 
Figure 6C, statistically different groups are represented with different letters.  The most 
striking differences were observed when Ro5 was used alone or in combination with COX-2 
inhibitors.  Ro5 + Indo treatment, Ro5 + DFU treatment, and Ro5 treatment alone were not 
found to be statistically different from each other, but these three regimens resulted in the 
highest mean progesterone levels.  However, Ro5 + Indo treatment was statistically different 
from Indo treatment alone.  Ro5 + DFU treatment was found to be statistically different from 
all treatments except Ro5 alone, Indo alone, and Ro5 + Indo.  In addition, Ro5 treatment 
alone was not statistically different from Indo treatment alone.  The results obtained were not 
attributable to toxic effects of the treatments.  Cell viability after treatment with LH (0.5 
ng/ml) with COX-2 inhibitors and TSPO drug ligands either singly or together, was 
determined with the MTT assay.  A maximally stimulating dose of 10 ng/mL LH was also 
tested.  As can be seen in Figure 7, cell viability was not affected by any of the treatments 




      Finally, we wished to assess whether using COX-2 inhibitors and TSPO drug ligands in 
combination had a different outcome than using the inhibitors and ligands separately, but in 
experiments in which the cells were stimulated  with dbcAMP rather than with LH.  The 
results are shown in Figure 8, and groups that are not statistically different from each other 
are represented by the same letter.  The three regimens with the highest mean progesterone 
levels were 5 µM Indo alone, 10 µM Indo alone, and Ro5 + 5 µM Indo.  These three 
treatments were not statistically different from each other.  However, treatment with 10 µM 
Indo alone had mean progesterone levels slightly lower than the other two treatments, and 
this regimen was not statistically different from treatment with Ro5 + DFU, Ro5 + 10 µM 
Indo, FGIN + DFU, or FGIN + 5 µM Indo. 
     Indo treatment seemed to be eliciting higher mean progesterone levels with stimulation of 
both LH and dbcAMP, so we wanted to examine the effects of Indo on MA-10 cell steroid 
production in more detail.  Because earlier experiments consistently showed promise for 
increasing progesterone production with Indo treatment, we decided to test Indo at a higher 
concentration than was done previously.   In order to do this, MA-10 cells were treated with 
increasing concentrations of Indo.  MA-10 cells were cultured in a 24 well plate and treated 
with Indo concentrations ranging from 0.5 µM to 50 µM with either LH or dbcAMP 
stimulation.  Cells were incubated with Indo for 30 minutes, and then given LH at a 
concentration of 0.5 ng/mL or dbcAMP at a concentration of 0.1 mM. Cells were then 
incubated for two hours and medium samples were collected and frozen.  Progesterone levels 
were measured by RIA.  As with our previous experiments, mean progesterone levels were 
consistently higher when cells were stimulated with dbcAMP compared to those stimulated 




are represented by the same letter.  Progesterone levels increased when the concentration of 
Indo increased, but declined when 50 µM Indo and dbcAMP stimulation were used, 
signifying possible toxic effects at this high concentration.  However, treatments with 
dbcAMP and Indo at a concentration of 1.0 µM, 5 µM, 10 µM, and 50 µM were not 
statistically different from each other.  All Indo treatments with LH were found to not be 
statistically different, except for LH treatment with 50 µM Indo.  Treatment with 50 µM Indo 
and LH was not found to be statistically different from treatment with dbcAMP and Indo 
concentrations at 0.5 µM, 1.0 µM, 5.0 µM, and 50 µM. 
















      COX-2 inhibitors and TSPO drug ligands each have been shown to have stimulatory 
effects on steroid production (Chung et al., 2013; Wang et al., 2003).  TSPO drug ligands 
accomplish this by acting at the level of the TSPO component of the transduceosome to 
increase steroid production (Papadopoulos and Miller, 2012), whereas COX-2 inhibitors are 
thought to block the inhibitory action of COX-2 on Leydig cell steroid production (Wang et 
al., 2003).  While these principles have been illustrated by various experiments separately, 
there is a lack of data examining if a combination treatment of both TSPO drug ligands and 
COX-2 inhibitors can have additive or synergistic effects on steroid production in the Leydig 
cell.  To begin to explore this possibility, we first wished to identify COX-2 inhibitors to use 
in conjunction with the two TSPO drug ligands, FGIN-1-27 and Ro5-4864, found by Chung 
et al. (2013) to increase steroid hormone production in primary Leydig cells.  Both ligands 
were shown to increase testosterone production through direct activation of TSPO.  The 
results from this experiment led us to use both FGIN-1-27 and Ro5-4864 in our experimental 
paradigm. 
Because LH is necessary for stimulation of progesterone production by MA-10 cells, 
we first sought to determine which LH concentrations would be best to use in experiments 
with COX-2 inhibitors and TSPO drug ligands. Our goal was to find the lowest concentration 
of LH that can produce the greatest increase in progesterone production relative to levels 
produced by a maximally stimulating dose of LH (100 ng/mL).   Little effect was found at an 
LH concentration of 0.01 ng/ml.  Approximately half maximal stimulation was found at 0.1 
ng/ml, and maximal stimulation at 0.1 – 1.0 ng/ml.  From these results, most experiments 




effect of four different COX-2 inhibitors on progesterone production by MA-10 cells was 
determined. For these studies, MA-10 cells were cultured in a 24 well plate and treated with a 
combination of LH and increasing concentrations of the COX-2 inhibitors Apigenin, DFU, 
NS398, or indomethacin (Indo).  Surprisingly, we found that the four COX-2 inhibitors had 
similar effects across all concentrations when examined in conjunction with LH stimulation, 
though with DFU and Indo showing slightly higher mean progesterone production at 
particular concentrations.  This was true whether LH was used at 0.1 or 1.0 ng/l.  
Previous studies of COX-2 inhibitor effects had utilized MA-10 cells stimulated by 
dbcAMP, which bypasses the LH/LH receptor G protein coupling (Wang et al., 2003).  
Consequently, we repeated our studies of COX-2 inhibitors, but with dbcAMP stimulation.  
Two concentrations of dbcAMP were used, 0.1 or 0.05 mM.  When tested at concentrations 
of 1 µM and 3.3 µM and stimulated with 0.1 mM dbcAMP, DFU and Indo produced higher 
mean progesterone levels compared to the other COX-2 inhibitors.  However at 10 µM 
concentration, Apigenin and DFU had extremely high mean progesterone levels compared to 
the other COX-2 inhibitors. The same experiment then was conducted with the lower 
dbcAMP concentration (0.05 mM). DFU and Indo were the two COX-2 inhibitors shown to 
increase mean progesterone production compared to the other inhibitors tested across all 
concentrations.  
We then conducted studies designed to determine whether treating MA-10 cells with 
combinations of COX-2 inhibitor and TSPO drug ligand would affect MA-10 cell 
progesterone production differently than when the cells were treated with COX-2 inhibitor or 
TSPO drug ligand separately.  The studies were conducted with both LH and dbcAMP.  MA-




and COX-2 inhibitors plus  TSPO drug ligands.  The COX-2 inhibitors used were DFU or 
Indo, and the TSPO drug ligands used were FGIN or Ro5.   MA-10 cells were treated with 
LH at concentrations of 0.1 – 0.5 ng/ml.  While there was increased steroid production when 
cells were treated with Ro5 or Ro5 + Indo at 0.1 ng/mL LH stimulation, there were no 
statistical differences seen across all treatment regimens.  No statistical differences were 
observed between treatments when tested with 0.2 ng/mL LH stimulation.  With 0.5 ng/ml 
LH, there were statistical differences observed between treatments.   The most notable 
differences were observed when Ro5 was used alone or in combination with COX-2 
inhibitors.  Ro5 + Indo treatment, Ro5 + DFU treatment, and Ro5 treatment alone resulted in 
the highest mean progesterone levels and were not found to be statistically different from 
each other.  Cell viability was examined in cells stimulated with 0.5 ng/mL LH by MTT 
assay. There was no statistically significant difference in cell viability across the various 
treatment regimens, lending credibility to the data.   
In order to examine these differences in progesterone production in response to a 
combination of COX-2 inhibitor and TSPO drug ligand further, we elected to determine if 
stimulation with dbcAMP would also exhibit this same pattern.  The highest mean 
progesterone levels were seen with 5 µM Indo alone, 10 µM Indo alone, and Ro5 + 5 µM 
Indo, and these three treatments were not statistically different from each other.   
When the effects of Indo treatment at various concentrations was tested with either 
LH or dbcAMP stimulation, cells stimulated with dbcAMP resulted in higher mean 
progesterone levels.  Treatments with dbcAMP and Indo at a concentration of 1.0 µM, 5 µM, 
10 µM, and 50 µM were not statistically different from each other.  All Indo treatments with 




with LH and 50 µM Indo was not found to be statistically different from treatment with 
dbcAMP and Indo concentrations at 0.5 µM, 1.0 µM, 5.0 µM, and 50 µM. 
The hypothesis upon which these studies were based was that a combination 
treatment of COX-2 inhibitors and TSPO drug ligands would have a different effect on 
progesterone production, whether additive or synergistic, than either alone.   This did not 
prove to be the case.  Indeed, our results showed that the combination treatment sometimes 
decreases progesterone production, as when cells were treated with FGIN alone in 
comparison to FGIN plus DFU or FGIN plus Indo.  The results obtained apparently were not 
a consequence of cell viability differences, though further studies of different combinations 
of COX-2 inhibitor and TSPO drug ligand must be conducted.  Thus, although the 
mechanisms that are involved in how COX-2 inhibitors and TSPO drug ligands stimulate 
steroid formation differ, the two together have no greater effect than either alone when used 
with MA-10 cells.  The possibility of additive or synergistic effects has not been assessed 
using primary cells or in vivo.    
 With regard to the COX-2 studies, it should be noted that much of the past work 
involving MA-10 cells was done using dbcAMP, and this work formed our rationale for 
using dbcAMP in our experiments.  There were differences in the effects of COX-2 
inhibitors in particular when MA-10 cells were stimulated with dbcAMP compared to LH.   
The results suggest that the effects of COX-2 inhibitors may only be present when dbcAMP 
is used.  cAMP activates many cellular pathways in addition to the steroidogenic pathway, 
perhaps including those that could affect steroidogenesis.  Thus the COX-2 pathway may not 
be relevant under normal LH stimulation, but may become significant when dbcAMP 




be a side effect of this activated pathway.  If this hypothesis is correct, it leads to the question 
of whether dbcAMP should be used instead of LH when studying MA-10 cells, as has been 
done in past studies. While the mechanisms behind the differences between progesterone 
production in MA-10 cells stimulated with LH versus dbcAMP is unclear, future testing is 
needed in order to examine if the proposed combination treatment with COX-2 inhibitors 
(specifically Indo) and TSPO drug ligands is a viable option for increasing steroid production 

















Figure 1: Progesterone levels produced by MA-10 cells in response to increasing LH 









Figure 2A:  Mean progesterone levels produced by MA-10 cells. Cells were treated with 
COX-2 inhibitor for 30 min, and then with a combination of inhibitor plus 0.1 ng/ml LH for 









Figure 2B: Mean progesterone levels produced by MA-10 cells treated increasing 














































Figure 3A-3D: Comparison of progesterone levels produced by MA-10 cells treated with 












Figure 4A: Mean progesterone levels produced by MA-10 cells treated with COX-2 












Figure 4B: Mean progesterone levels produced by MA-10 cells treated with COX-2 inhibitor 
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Figure 5  
Figure 5: Combinations of treatments used when examining the effects of COX-2 inhibitor 
and TSPO drug ligand treatment on progesterone production.  Final COX-2 inhibitor and 









Figure 6A: Mean progesterone levels produced by MA-10 cells treated with TSPO drug 
ligands, COX-2 inhibitors, and LH at a concentration of 0.1 ng/mL.  COX-2 inhibitors used 
were DFU and Indo.  TSPO drug ligands used were Ro5 and FGIN.  The data are expressed 
as a mean +SEM of at least 3 experiments. (n=3-6).  Standard error bars were not expressed 











Figure 6B: Mean progesterone levels produced by MA-10 cells treated with TSPO drug 
ligands, COX-2 inhibitors, and LH at a concentration of 0.2 ng/mL.  COX-2 inhibitors used 
were DFU and Indo.  TSPO drug ligands used were Ro5 and FGIN.  The data are expressed 
as a mean +SEM of at least 3 experiments. (n=4-9).  No statistical difference was observed 









Figure 6C: Mean progesterone levels produced by MA-10 cells treated with TSPO drug 
ligands, COX-2 inhibitors, and LH at a concentration of 0.05 ng/mL.  COX-2 inhibitors used 
were DFU and Indo.  TSPO drug ligands used were Ro5 and FGIN.  Results were measured 
with radioimmunoassay.  The data are expressed as a mean +SEM of at least 3 experiments. 
(n=6-12). Statistical differences were observed between treatments (P<0.05), and groups that 








Figure 7: MTT Assay was performed on plates treated with COX-2 inhibitors and TSPO 
drug ligands in order to assess cell viability.  COX-2 inhibitors used were DFU and Indo.  
TSPO drug ligands used were Fo5 and FGIN.  After treatment, cells were provided with 
MTT for an additional hour.  The reduction of the MTT dye by the viable cells was read on 
plate reader at 562 nm wavelength.  The data are expressed as a mean +SEM of 3 











Figure 8: Mean progesterone levels produced by MA-10 cells treated with TSPO drug 
ligands, COX-2 inhibitors, and dbcAMP at a concentration of 0.05 mM.  COX-2 inhibitors 
used were DFU and Indo.  TSPO drug ligands used were Ro5 and FGIN.  Results were 
measured with radioimmunoassay.  The data are expressed as a mean +SEM of at least 3 
experiments (n=3-24).  Statistical differences were observed between treatments (P<0.05), 










Figure 9: Mean progesterone levels in ng/mL produced by MA-10 cells treated with the 
COX-2 inhibitor Indo on a dose curve and LH at a concentration of 0.5 ng/mL or dbcAMP at 
a concentration of 0.1 mM.  Indo concentration s ranged from 0.5 µM to 50 µM.  Results 
were measured with radioimmunoassay.  The data are expressed as a mean +SEM of 8 
experiments. (n=8).  Statistical differences were observed between treatments (P<0.05) and 
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